Cannabinoids and multiple sclerosis

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB1 and/or CB2 receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.

Original languageEnglish
Pages (from-to)45-59
Number of pages15
JournalMolecular Neurobiology
Volume36
Issue number1
Early online date26 Jun 2007
DOIs
Publication statusPublished - Aug 2007

Keywords

  • Delta(9)-tetrahydrocannabinol
  • dronabinol
  • Marinol (R)
  • Sativex (R)
  • nabilone
  • Cesamet (R)
  • multiple sclerosis
  • spasticity
  • pain
  • cannabinoid receptors
  • endocannabinoids
  • anandamide
  • 2-arachidonoyl glycerol
  • experimental autoimmune encephalomyelitis
  • anandamide cellular uptake
  • acid amide hydrolase
  • experimental allergic encephalomyelitis autoantibodies
  • orally-administered cannabinoids
  • placebo-controlled trial
  • chronic pain models
  • head group analogs
  • neuropathic pain
  • CB2 receptor

Cite this